NUVB Earnings — Nuvation Bio Inc. Post-ER Performance | BigEarnings
NUVB — Nuvation Bio Inc.
XNYS · Healthcare · Biotechnology
Price$4.78
Market Cap$1.7B
P/E—
52W Range$1.57 – $9.75
Next Earnings2026-08-06
About Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
